NO20092729L - Lipasevarianter for farmasoytisk anvendelse - Google Patents
Lipasevarianter for farmasoytisk anvendelseInfo
- Publication number
- NO20092729L NO20092729L NO20092729A NO20092729A NO20092729L NO 20092729 L NO20092729 L NO 20092729L NO 20092729 A NO20092729 A NO 20092729A NO 20092729 A NO20092729 A NO 20092729A NO 20092729 L NO20092729 L NO 20092729L
- Authority
- NO
- Norway
- Prior art keywords
- lipases
- digestive
- improved
- pharmaceutical use
- diabetes
- Prior art date
Links
- 239000004367 Lipase Substances 0.000 title abstract 5
- 102000004882 Lipase Human genes 0.000 title abstract 5
- 108090001060 Lipase Proteins 0.000 title abstract 5
- 235000019421 lipase Nutrition 0.000 title abstract 5
- 241000223258 Thermomyces lanuginosus Species 0.000 abstract 3
- 230000001079 digestive effect Effects 0.000 abstract 3
- 108091005804 Peptidases Proteins 0.000 abstract 2
- 239000004365 Protease Substances 0.000 abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 239000004382 Amylase Substances 0.000 abstract 1
- 102000013142 Amylases Human genes 0.000 abstract 1
- 108010065511 Amylases Proteins 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 102000057297 Pepsin A Human genes 0.000 abstract 1
- 108090000284 Pepsin A Proteins 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 235000019418 amylase Nutrition 0.000 abstract 1
- 239000003833 bile salt Substances 0.000 abstract 1
- 229940093761 bile salts Drugs 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229940111202 pepsin Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87119606P | 2006-12-21 | 2006-12-21 | |
| PCT/US2007/087168 WO2008079685A2 (en) | 2006-12-21 | 2007-12-12 | Lipase variants for pharmaceutical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092729L true NO20092729L (no) | 2009-09-18 |
Family
ID=38043020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092729A NO20092729L (no) | 2006-12-21 | 2009-07-20 | Lipasevarianter for farmasoytisk anvendelse |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8273348B2 (enExample) |
| EP (6) | EP2261328B1 (enExample) |
| JP (1) | JP5406040B2 (enExample) |
| KR (1) | KR20090101930A (enExample) |
| CN (2) | CN105112386A (enExample) |
| AR (1) | AR064494A1 (enExample) |
| AU (1) | AU2007337150A1 (enExample) |
| BR (1) | BRPI0721103A2 (enExample) |
| CA (3) | CA3081308C (enExample) |
| IL (1) | IL198893A0 (enExample) |
| MX (1) | MX2009006597A (enExample) |
| NO (1) | NO20092729L (enExample) |
| RU (1) | RU2009128067A (enExample) |
| TW (1) | TW200829698A (enExample) |
| WO (1) | WO2008079685A2 (enExample) |
| ZA (1) | ZA200903598B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2314646T3 (es) | 2004-03-22 | 2009-03-16 | Solvay Pharmaceuticals Gmbh | Composiciones farmaceuticas por via de productos que contienen lipasa , en particular de pancreatina, que contienen tensioactivos. |
| HUE031042T2 (en) | 2005-07-29 | 2017-06-28 | Abbott Laboratories Gmbh | Methods for producing pancreatin powder with low viral content |
| US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
| US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
| US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| US8273348B2 (en) * | 2006-12-21 | 2012-09-25 | Novozymes A/S | Lipase variants for pharmaceutical use |
| BRPI0909707A2 (pt) * | 2008-02-29 | 2015-08-25 | Procter & Gamble | Composição detergente que compreende lipase. |
| MX2010009464A (es) | 2008-02-29 | 2010-09-22 | Dsm Ip Assets Bv | Lipasas con alta especificidad hacia acidos grasos de cadena corta y usos de las mismas. |
| CN101990573B (zh) * | 2008-02-29 | 2014-01-22 | 诺维信公司 | 具有改进的稳定性的脂肪分解酶变体及编码该变体的多核苷酸 |
| MX2012006616A (es) | 2009-12-09 | 2012-06-21 | Procter & Gamble | Productos para el cuidado de las telas y el hogar. |
| DK2734633T3 (da) | 2011-07-22 | 2019-06-11 | Novozymes North America Inc | Fremgangsmåder til forbehandling af celluloseholdigt materiale og forbedring af hydrolyse deraf |
| US8268305B1 (en) | 2011-09-23 | 2012-09-18 | Bio-Cat, Inc. | Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase |
| US9809787B2 (en) * | 2011-12-29 | 2017-11-07 | Novozymes A/S | Detergent compositions comprising lipase |
| DK3211074T3 (da) * | 2012-02-03 | 2020-06-02 | Novozymes As | Lipasevarianter og polynukleotider, som koder for dem |
| WO2013149858A1 (en) | 2012-04-02 | 2013-10-10 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| CN110093330B (zh) * | 2012-10-12 | 2023-11-28 | 丹尼斯科美国公司 | 包含脂解酶变体的组合物和方法 |
| MY192746A (en) | 2013-05-14 | 2022-09-06 | Novozymes As | Detergent compositions |
| EP3696264B1 (en) * | 2013-07-19 | 2023-06-28 | Danisco US Inc. | Compositions and methods comprising a lipolytic enzyme variant |
| WO2016079305A1 (en) * | 2014-11-20 | 2016-05-26 | Novozymes A/S | Alicyclobacillus variants and polynucleotides encoding same |
| US10457921B2 (en) | 2014-12-05 | 2019-10-29 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| WO2016091870A1 (en) * | 2014-12-09 | 2016-06-16 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| EP3280818A2 (en) | 2015-04-07 | 2018-02-14 | Novozymes A/S | Methods for selecting enzymes having lipase activity |
| CA3175255A1 (en) * | 2015-07-01 | 2017-01-05 | Novozymes A/S | Methods of reducing odor |
| US10760037B2 (en) * | 2015-07-03 | 2020-09-01 | Novozymes A/S | Sulfite compositions |
| WO2018015295A1 (en) | 2016-07-18 | 2018-01-25 | Novozymes A/S | Lipase variants, polynucleotides encoding same and the use thereof |
| EP3575398A4 (en) * | 2017-01-30 | 2020-11-11 | Nippon Medical School Foundation | ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT |
| CA3072932C (en) | 2017-09-27 | 2023-09-26 | The Procter & Gamble Company | Detergent compositions comprising lipases |
| CA3073362A1 (en) * | 2017-09-27 | 2019-04-04 | Novozymes A/S | Lipase variants and microcapsule compositions comprising such lipase variants |
| CN111757930A (zh) * | 2018-02-08 | 2020-10-09 | 诺维信公司 | 脂肪酶变体及其组合物 |
| CA3109082A1 (en) * | 2018-08-16 | 2020-02-20 | Isolere Bio, Inc. | Genetically encoded polypeptide for affinity capture and purification of biologics |
| CN111334369B (zh) * | 2020-03-11 | 2022-10-21 | 陕西科技大学 | 一种酶法制备卵磷脂型pufa的方法 |
| EP4172325A1 (en) * | 2020-06-24 | 2023-05-03 | Cilian AG | New lipase enzyme |
| US20240035005A1 (en) * | 2020-10-29 | 2024-02-01 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
| CN113846074B (zh) * | 2021-10-20 | 2022-10-21 | 南京林业大学 | 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用 |
| CN116732002A (zh) * | 2022-03-01 | 2023-09-12 | 中国科学院天津工业生物技术研究所 | 一种耐受表面活性剂的脂肪酶变体及其应用 |
| US20250311734A1 (en) | 2022-05-14 | 2025-10-09 | Novozymes A/S | Compositions and Methods for Preventing, Treating, Suppressing and/or Eliminatting Phytopathogenic Infestations and Infections |
| US20250368924A1 (en) * | 2022-06-24 | 2025-12-04 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
| CN120082537B (zh) * | 2023-12-01 | 2026-03-17 | 青岛蔚蓝生物集团有限公司 | 一种脂肪酶突变体 |
| TWI903491B (zh) * | 2024-05-09 | 2025-11-01 | 國立高雄科技大學 | 水體與沉積物通量培養系統 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK173590D0 (da) | 1990-06-06 | 1990-07-19 | Novo Nordisk As | Rekombinante terapeutiske lipaser |
| US5869438A (en) | 1990-09-13 | 1999-02-09 | Novo Nordisk A/S | Lipase variants |
| DK46693D0 (enExample) * | 1993-04-23 | 1993-04-23 | Novo Nordisk As | |
| DK0548228T3 (da) * | 1990-09-13 | 1999-05-10 | Novo Nordisk As | Lipasevarianter |
| CA2095852C (en) | 1990-12-05 | 2001-05-08 | Uffe Lovborg | Proteins with changed epitopes and methods for the production thereof |
| JPH06507071A (ja) | 1991-05-01 | 1994-08-11 | ノボザイムス アクティーゼルスカブ | 安定化酵素 |
| DK39693D0 (da) | 1993-04-02 | 1993-04-02 | Novo Nordisk As | Enzym |
| WO1995009909A1 (en) | 1993-10-04 | 1995-04-13 | Novo Nordisk A/S | An enzyme preparation comprising a modified enzyme |
| MX9603542A (es) | 1994-02-22 | 1997-03-29 | Novo Nordisk As | Metodo para preparar una variante de una enzima lipolitica. |
| AU3924095A (en) | 1994-11-24 | 1996-06-17 | Novo Nordisk A/S | A process for producing polypeptides with reduced allergenicity |
| AU697440B2 (en) | 1994-12-07 | 1998-10-08 | Novozymes A/S | Polypeptide with reduced allergenicity |
| EP0805856B2 (en) | 1995-01-26 | 2009-04-01 | Novozymes A/S | Animal feed additives comprising xylanase |
| EP0839186B1 (en) | 1995-07-14 | 2004-11-10 | Novozymes A/S | A modified enzyme with lipolytic activity |
| US6495357B1 (en) | 1995-07-14 | 2002-12-17 | Novozyme A/S | Lipolytic enzymes |
| JP4068142B2 (ja) | 1995-08-11 | 2008-03-26 | ノボザイムス アクティーゼルスカブ | 新規の脂肪分解酵素 |
| JP2002510963A (ja) | 1997-01-10 | 2002-04-09 | ノボザイムス アクティーゼルスカブ | スキンケア用酵素修飾体 |
| JP2001511162A (ja) | 1997-02-06 | 2001-08-07 | ノボ ノルディスク アクティーゼルスカブ | 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体 |
| WO1999000489A1 (en) | 1997-06-25 | 1999-01-07 | Novo Nordisk A/S | A modified polypeptide |
| AU3247699A (en) | 1998-02-17 | 1999-09-06 | Novo Nordisk A/S | Lipase variant |
| ATE328070T1 (de) * | 1998-02-17 | 2006-06-15 | Novozymes As | Lipasevariante |
| CN1323345A (zh) | 1998-10-13 | 2001-11-21 | 诺沃奇梅兹有限公司 | 具有降低的免疫应答的修饰多肽 |
| JP2003500003A (ja) | 1998-10-30 | 2003-01-07 | ノボザイムス アクティーゼルスカブ | 低いアレルゲン性のタンパク質変異型 |
| ATE365210T1 (de) | 1998-10-30 | 2007-07-15 | Novozymes As | Glykosylierte proteine mit reduzierter allergenität |
| US7312062B2 (en) * | 1998-11-27 | 2007-12-25 | Novozymes A/S | Lipolytic enzyme variants |
| EP1131416B1 (en) | 1998-11-27 | 2009-09-02 | Novozymes A/S | Lipolytic enzyme variants |
| EP1162995B1 (de) | 1999-03-17 | 2003-06-04 | Solvay Pharmaceuticals GmbH | Enzyme zur behandlung von diabetes mellitus typ i |
| KR20010108379A (ko) * | 1999-03-31 | 2001-12-07 | 피아 스타르 | 리파제 변이체 |
| EP2278000A1 (en) * | 1999-03-31 | 2011-01-26 | Novozymes A/S | Lipase variant |
| KR20020077421A (ko) | 2000-02-08 | 2002-10-11 | 에프. 호프만-라 로슈 아게 | 동물 사료에서 산-안정성 서브틸리신 프로테아제의 사용 |
| CA2406621A1 (en) * | 2000-04-28 | 2001-11-08 | Novozymes A/S | Protein variants having modified immunogenicity |
| CA2431972C (en) * | 2001-01-10 | 2012-10-23 | Novozymes A/S | Thermostable lipolytic enzyme variant |
| AR032392A1 (es) * | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado. |
| JP4287149B2 (ja) | 2001-02-07 | 2009-07-01 | ノボザイムス アクティーゼルスカブ | リパーゼ変異体 |
| DK2295556T3 (en) | 2002-01-16 | 2015-01-26 | Novozymes As | Lipolytic Enzyme Variants and Method of Preparation thereof. |
| AU2004208860A1 (en) | 2003-02-06 | 2004-08-19 | Novozymes A/S | Human heavy chain antibody expression in filamentous fungi |
| EP2290057A3 (en) | 2003-05-09 | 2011-08-03 | Novozymes A/S | Variant lipolytic enzymes |
| US20060236414A1 (en) | 2003-06-19 | 2006-10-19 | Novozymes A/S | Proteases and methods for producing them |
| US20060251763A1 (en) | 2003-06-19 | 2006-11-09 | Patkar Shamkant A | Phospholipase variants |
| WO2005070962A1 (en) | 2004-01-21 | 2005-08-04 | Novozymes A/S | Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell |
| ES2314646T3 (es) | 2004-03-22 | 2009-03-16 | Solvay Pharmaceuticals Gmbh | Composiciones farmaceuticas por via de productos que contienen lipasa , en particular de pancreatina, que contienen tensioactivos. |
| SI1809320T1 (sl) | 2004-10-14 | 2010-11-30 | Cystic Fibrosis Foundation Therapeutics Inc | Sestavki ki vsebujejo lipazo proteazo in amilazo za zdravljenje pankreasne insuficience |
| EP1851311A2 (en) | 2005-02-10 | 2007-11-07 | Novozymes A/S | Enzymatic enantioselective ester or amide hydrolysis or synthesis |
| AU2006261443A1 (en) | 2005-06-24 | 2006-12-28 | Novozymes A/S | Proteases for pharmaceutical use |
| EP1896057A2 (en) | 2005-06-24 | 2008-03-12 | Novozymes A/S | Amylases for pharmaceutical use |
| US20090047266A1 (en) * | 2005-06-24 | 2009-02-19 | Novozymes A/S | Lipases for Pharmaceutical Use |
| WO2007080197A2 (en) * | 2006-01-16 | 2007-07-19 | Novozymes A/S | Immobilised enzymes |
| ES2629332T3 (es) * | 2006-01-23 | 2017-08-08 | Novozymes A/S | Variantes de lipasa |
| JP2009523900A (ja) | 2006-01-23 | 2009-06-25 | ザ プロクター アンド ギャンブル カンパニー | リパーゼと漂白剤触媒を含む組成物 |
| US8273348B2 (en) * | 2006-12-21 | 2012-09-25 | Novozymes A/S | Lipase variants for pharmaceutical use |
-
2007
- 2007-12-12 US US12/519,868 patent/US8273348B2/en active Active
- 2007-12-12 EP EP10172609.9A patent/EP2261328B1/en active Active
- 2007-12-12 CA CA3081308A patent/CA3081308C/en active Active
- 2007-12-12 MX MX2009006597A patent/MX2009006597A/es not_active Application Discontinuation
- 2007-12-12 WO PCT/US2007/087168 patent/WO2008079685A2/en not_active Ceased
- 2007-12-12 CA CA2961041A patent/CA2961041C/en active Active
- 2007-12-12 CN CN201510504893.8A patent/CN105112386A/zh active Pending
- 2007-12-12 CN CN200780051638.6A patent/CN101743308B/zh active Active
- 2007-12-12 AU AU2007337150A patent/AU2007337150A1/en not_active Abandoned
- 2007-12-12 EP EP12155319.2A patent/EP2455462B1/en active Active
- 2007-12-12 RU RU2009128067/10A patent/RU2009128067A/ru not_active Application Discontinuation
- 2007-12-12 JP JP2009543078A patent/JP5406040B2/ja active Active
- 2007-12-12 EP EP12155317.6A patent/EP2455461B1/en active Active
- 2007-12-12 CA CA2670643A patent/CA2670643C/en active Active
- 2007-12-12 BR BRPI0721103-1A patent/BRPI0721103A2/pt not_active IP Right Cessation
- 2007-12-12 EP EP12155294.7A patent/EP2455459B1/en active Active
- 2007-12-12 KR KR1020097014850A patent/KR20090101930A/ko not_active Withdrawn
- 2007-12-12 EP EP07869130A patent/EP2099907A2/en not_active Withdrawn
- 2007-12-12 EP EP12155315A patent/EP2455460A3/en not_active Withdrawn
- 2007-12-18 TW TW096148377A patent/TW200829698A/zh unknown
- 2007-12-21 AR ARP070105859A patent/AR064494A1/es not_active Application Discontinuation
-
2009
- 2009-05-21 IL IL198893A patent/IL198893A0/en unknown
- 2009-05-25 ZA ZA200903598A patent/ZA200903598B/xx unknown
- 2009-07-20 NO NO20092729A patent/NO20092729L/no not_active Application Discontinuation
-
2012
- 2012-08-16 US US13/587,043 patent/US9029115B2/en active Active
-
2015
- 2015-04-06 US US14/679,563 patent/US9539311B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006597A (es) | Variantes de lipasa para uso farmaceutico. | |
| NO20080437L (no) | Lipaser til farmasoytisk anvendelse | |
| Cornaciu et al. | The minimal domain of adipose triglyceride lipase (ATGL) ranges until leucine 254 and can be activated and inhibited by CGI-58 and G0S2, respectively | |
| Draganov | Lactonases with oragnophosphatase activity: structural and evolutionary perspectives | |
| Parzych et al. | Vacuolar hydrolysis and efflux: current knowledge and unanswered questions | |
| DK1755656T3 (da) | Enzymer til farmaceutisk anvendelse | |
| NO20080439L (no) | Amylaser til farmasoytisk anvendelse | |
| JP2010512795A5 (enExample) | ||
| NL300874I2 (nl) | Elosulfase alfa | |
| RU2011102781A (ru) | ПРИМЕНЕНИЕ Hsp70 В КАЧЕСТВЕ РЕГУЛЯТОРА ФЕРМЕНТАТИВНОЙ АКТИВНОСТИ | |
| DK1162995T3 (da) | Enzymer til behandling af diabetes mellitus type I | |
| EP4241854A3 (en) | Lysosomal storage disease enzyme | |
| Chandrasekaran et al. | In search of a catalytic bioscavenger for the prophylaxis of nerve agent toxicity | |
| MX2010005690A (es) | Variantes de proteasa para uso farmaceutico. | |
| MX2007015474A (es) | Proteasas para uso farmaceutico. | |
| US11584920B2 (en) | Use of enzymes with a wide pH activity range as medicaments for promoting digestion | |
| Mandrich et al. | Hyperthermophilic phosphotriesterases/lactonases for the environment and human health | |
| TH105721A (th) | แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม | |
| TH88730A (th) | ไลเปสสำหรับการใช้ทางเภสัชกรรม | |
| Allahyari et al. | Diisopropyl-fluorophosphatase as a catalytic bioscavenger | |
| TH105721B (th) | แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม | |
| WO2008040739A3 (en) | Lipolytic enzyme variants | |
| Roy et al. | Expression of recombinant human cathepsin K is enhanced by codon optimization | |
| Copley et al. | A compromise required by gene sharing enables survival: implications for evolution of novel enzyme activities | |
| Ruiz | Transcriptional and post-transcriptional regulation of synaptic acetylcholinesterase in skeletal muscle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |